BIAF

$2.73-0.24 (-8.08%)

Market ClosedAs of Mar 20, 8:00 PM UTC

bioAffinity Technologies, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Recent News

Associated Press Finance
Mar 17, 2026

BC-Most Active Stocks

YY Group Holdings Ltd. 64,558,078 0.055

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 5, 2026

BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?

bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead? Let's see.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Nov 19, 2025

BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss

bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Aug 21, 2025

BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth

bioAffinity shifts its focus on CyPath Lung as the second-quarter 2025 loss widens, with rising adoption and new market expansion underway.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Jul 1, 2025

The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies

META, NOW, and BKNG lead with AI-driven growth and digital transformation tailwinds, while VASO and BIAF offer speculative upside.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.